PARI Devices used in SHIP Study of Hypertonic Saline in Preschoolers with Cystic Fibrosis

Thursday, November 29, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

MIDLOTHIAN, Va., Nov. 29, 2018 /PRNewswire/ -- A recent study in preschoolers with cystic fibrosis (CF) conducted by Cystic

Fibrosis Foundation Therapeutics used PARI's LC Sprint Jr. nebulizer, Vios PRO compressor,  and PARI's 7% hypertonic saline. The study called SHIP (Saline Hypertonic in Preschoolers) showed that PARI's 7% hypertonic saline inhaled twice daily using the
PARI LC Sprint Jr. and the Vios PRO compressor resulted in a sustained and significant improvement in a lung function test called the lung clearance index over 48 weeks.

"PARI was the first company in the USA to receive clearance to market by the FDA for hypertonic saline 7% inhalation solution in unit-dose form, which includes production under Good Manufacturing Practice (GMP) conditions to ensure consistency. We are pleased that researchers chose PARI's aerosol delivery devices and hypertonic saline for the SHIP Study and the positive results show that treatment with hypertonic saline can benefit preschoolers with CF" said Lisa Cambridge, director of medical science at PARI.

The results from the SHIP study were presented last month at the North American Cystic Fibrosis Conference in Denver, CO. The study compared nebulized 7% hypertonic saline to 0.9% isotonic saline in children 3-5 years of age with CF. The study found that nebulized 7% hypertonic saline after pre-treatment with albuterol significantly improved the lung clearance index over 48 weeks compared to 0.9% saline (the control agent).

Hypertonic saline is commonly used by people with CF to help thin mucus in the lungs and promote airway clearance.

About Cystic FibrosisCystic fibrosis, a progressive, genetic disease affecting 30,000 people in the US; it is caused by a genetic mutation that results in poorly hydrated, thickened mucus secretions in the lungs.

About PARI Respiratory Equipment, Inc. PARI is a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP.  PARI's worldwide mission is to improve the lives of those affected by respiratory diseases and those who provide care for them. This is reflected in our comprehensive portfolio of innovative products. PARI is considered the gold standard in aerosol delivery for nebulizer therapies. Featured products include Kitabis Pak (co-packaging of tobramycin inhalation solution and PARI LC PLUS Nebulizer), PARI LC PLUS and LC Sprint Reusable Nebulizers, Vortex® Holding Chamber, and the drug-specific eFlow Technology platform.


Cision View original content:

SOURCE PARI Respiratory Equipment, Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store